Pleasanton, California (PRWEB) February 06, 2014
Sanarus Technologies is pleased to announce the signing of a co-development agreement with The Centre for Surgical Invention and Innovation (CSii), creators of the new Image Guided Automatic Robotic (IGAR) system IGAR-Breast.
Sanarus Technologies is a privately held medical device company specializing in minimally invasive solutions with a focus on developing safe and effective products for the treatment of breast disease. Under terms of the agreement, Sanarus’ proprietary cryoablation technology will be incorporated into CSii’s IGAR technology.
“As the inventor of cryotherapy for breast tumors, Sanarus supports the continuing evolution of technology-enabled healing,” as stated from BJ Hardman, CEO of Sanarus. “Co-developing an integrated next generation device that enables tumors to be detected and treated in one office visit will assure that we are being true to our vision. Sanarus is delighted to be working with CSii to deliver new medical devices that help shape the future of healthcare.”
The Centre for Surgical Innovation (CSii), located in Hamilton, Canada, designed the IGAR system in collaboration with MacDonald Dettwiler and Associates (MDA), creators of the Canadarm, Canadarm 2 and Dexter. MDA robotic devices have been successfully deployed on numerous space missions as well as the International Space Station (ISS).
“The IGAR-Breast system is a sophisticated and highly targeted delivery system that will perfectly align with Sanarus cryoablation technology to create an efficient and effective treatment for breast tumors,” said Dr. Mehran Anvari, CEO and Scientific Director of CSii. “It is a collaboration that holds great potential and I look forward to working with the team at Sanarus Technologies to help create new standards of excellence and new efficiencies in the detection and treatment of breast tumors and more.”
The IGAR-Breast robotic system is designed to work in combination with an MRI scanner, which is highly sensitive to early detection of breast lesions. The radiologist uses specially designed software to tag the potential target and tell IGAR what path to take. The software then helps the radiologist to make sure he or she is accurately hitting the right area. Incorporating cryoablation into IGAR technology enables the patient to be diagnosed and treated in the same office visit.
The Sanarus Visica 2™ Treatment System is fully developed with 510k FDA clearance for cancerous tissue and benign breast fibroadenomas. Thousands of minimally invasive procedures have been performed on benign breast tumors in an out-patient environment.
Sanarus and CSii are delighted to be working collaboratively to develop innovative technology that will enhance the medical standard of care for breast tumors. Co-development will enable both companies to leverage R&D strengths while driving both awareness and availability of this next generation solution for all women.